SCHEMBL30657191

SCHEMBL30657191

O=C(O)c1ccc(-c2nn(C(=O)c3c(Cl)cccc3C(F)(F)F)c3ccccc23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
RORC P51449 17/20 1.00
PPARG P37231 1/20 1.00
RARG P13631 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11903924 1.00 RORC (1.00) RORCPPARGRARG
SCHEMBL12470435 0.99 RORC (0.98) RORCPPARGRARG
SCHEMBL15566900 0.91 RORC (0.85) RORCPPARG
SCHEMBL12470433 0.90 RORC (0.81) RORCPPARGRARG
SCHEMBL11904038 0.89 RORC (1.00) RORCPPARGRARG
SCHEMBL19840238 0.89 RORC (0.80) RORCPPARGRARG
SCHEMBL11904117 0.88 RORC (0.79) RORCPPARGRARG
SCHEMBL12470727 0.88 RORC (0.86) RORCPPARG
SCHEMBL12471015 0.88 RORC (0.81) RORCPPARG
SCHEMBL12470446 0.88 RORC (0.79) RORCPPARGRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099543-A1 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND CANCER UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. 2025-03-27 US disclosed
US-20250059154-A1 CYSTEINE-DEPENDENT INVERSE AGONISTS OF NUCLEAR RECEPTORS ROR-GAMMA/ROR-GAMMA-T AND METHODS OF TREATING DISEASES OR DISORDERS THEREWITH REATA PHARMACEUTICALS, INC. (US) 2025-02-20 US disclosed
CN-116715676-B Novel small molecular fluorescent probe for targeting ROR gamma and preparation method and application thereof 南京中医药大学 2024-11-26 CN disclosed
US-12109249-B2 Compositions and methods for treating inflammation and cancer UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2024-10-08 US disclosed
US-12060340-B2 Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith REATA PHARMACEUTICALS, INC (US) 2024-08-13 US disclosed
CN-116715676-A Novel small molecular fluorescent probe for targeting ROR gamma and preparation method and application thereof 南京中医药大学 2023-09-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060340-B2 Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith RORC, RORA, RORB RORC 1/4885PPARG 17/4885RARG 14/4885
US-20250059154-A1 CYSTEINE-DEPENDENT INVERSE AGONISTS OF NUCLEAR RECEPTORS ROR-GAMMA/ROR-GAMMA-T AND METHODS OF TREATING DISEASES OR DISORDERS THEREWITH RORC, RORA, RORB RORC 1/4885PPARG 17/4885RARG 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.